VIA Pharmaceuticals (VIA Pharmaceuticals) GF Value : $0.00 (As of Jun. 21, 2024)

View and export this data going back to 1998. Start your Free Trial

What is VIA Pharmaceuticals GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-06-21), VIA Pharmaceuticals's share price is $0.0005. VIA Pharmaceuticals's GF Value is $0.00. Therefore, VIA Pharmaceuticals's Price-to-GF-Value for today is .

Based on the relationship between the current stock price and the GF Value, GuruFocus believes VIA Pharmaceuticals is Not Valued.

VIA Pharmaceuticals (GREY:VIAP) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

VIA Pharmaceuticals's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	0.0005	/	0.00
	=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VIA Pharmaceuticals GF Value Related Terms

Thank you for viewing the detailed overview of VIA Pharmaceuticals's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

VIA Pharmaceuticals (VIA Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIA Pharmaceuticals Inc (GREY:VIAP) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

750 Battery Street, Suite 330, San Francisco, CA, USA, 94111

Website

http://www.baycitycapital.com

VIA Pharmaceuticals Inc is a development stage biotechnology company focuses on the development of small-molecule drugs to treat cardiovascular and metabolic diseases.

Executives

Fred B Craves	director	750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
Bay City Capital Fund Iv, L.p.	10 percent owner	750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Bay City Capital Management Iv Llc	10 percent owner	750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Bay City Capital Fund Iv Co Invesment Fund Lp	10 percent owner	750 BATTERY ST STE 400, SAN FRANCISCO CA 94111
Bay City Capital Llc	10 percent owner	750 BATTERY STREET STE 400, SAN FRANCISCO CA 94111
Douglas B Given	director	C/O NEORX CORP, 410 WEST HARRISON ST, SEATTLE WA 98119
Karen Steil Wright	officer: V.P. ? Finance, Controller	750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Lawrence Kenneth Cohen	director, officer: CEO and President	750 BATTERY STREET, SUITE 330 SAN FRANCISCO CA 94111
Richard L Anderson	director	14031 216TH WAY NE, WOODINVILLE WA 98072
Mark Bagnall	director	3876 BAY CENTER PLACE, HAYWARD CA 94545
Rebecca Taub	officer: SVP, Research & Development	750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Adeoye Y Olukotun	officer: Chief Medical Officer	3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Deerfield Special Situations Fund International Ltd	10 percent owner, other: Possible Member of 10% Group	BISON COURT, ROAD TOWN, TORTOLA D8 -
Deerfield Special Situations Fund, L.p.	10 percent owner, other: Possible Member of 10% Group	780 3RD AVENUE, 37TH FLOOR, NEW YORK NY 10017
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017

VIA Pharmaceuticals (VIA Pharmaceuticals) Headlines

From GuruFocus

VIA Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-12-2009

VIA Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 08-12-2009